Clinical trials: Anlotinib
Non-small Cell Lung Cancer
Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0303）
Evaluate the efficacy and safety of Anlotinib as the 3-line treatment of patients with advanced non-small lung cancer, with placebo control.
- Trial name
- ALTER0303 (NCT02388919)
- Testing
- Anlotinib
- Where
- 40 sites in China
- Volunteers
- 439 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NSCLC
Efficacy and Safety Analysis of ICIs Plus Angiogenesis Inhibitors for Treatment of Advanced NSCLC in Elderly Patients
Immune checkpoint inhibitors(ICIs) combined with angiogenesis inhibitors may is synergistic in elderly patients with advanced non-small cell lung cancer(NSCLC), however its true efficacy is still unclear.
- Trial name
- IMAGINE (NCT05688046)
- Testing
- Immune checkpoint inhibitors plus angiogenesis inhibitors, Immune checkpoint inhibitors without angiogenesis inhibitors
- Where
- China
- Volunteers
- 79 people
- Sponsor
- Suzhou Municipal Hospital
Hepatocellular Carcinoma
Anlotinib and TQB2450 in Advanced Hepatocellular Carcinoma After Failure of Prior Immune Checkpoint Inhibitors
This is an multi-center, single arm, exploratory study to evaluate the efficacy and safety of anlitinib combined with TQB2450 in patients with advanced hepatocellular carcinoma （HCC）who failed prior immune checkpoint inhibitor…
- Trial name
- FAITH (NCT06031480)
- Testing
- Anlotinib and TQB2450
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Shanghai Zhongshan Hospital
Nasopharyngeal Carcinoma
A Study of Penpulimab Combination Therapy in Patients With Advanced Nasopharyngeal Carcinoma
This is a multi-center, randomized, open-label, phase II study to evaluate the efficacy and safety of anti-PD-1 antibody Penpulimab (AK105) combined with chemotherapy ± anlotinib hydrochloride in the first-line treatment of…
- Trial name
- NCT04736810
- Testing
- AK105, Cisplatin, Gemcitabine
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Akeso
Non-small Cell Lung Cancer
Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer
This study aims to explore the efficacy of Anlotinib with or without Immune Checkpoint Inhibitor in Standard Chemo-immunotherapy Failed Advanced NSCLC.
- Trial name
- ATHENA (NCT04322617)
- Testing
- Anlotinib plus the same Immune Checkpoint Inhibitors., Anlotinib plus the new Immune Checkpoint Inhibitors., Anlotinib
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- Hunan Province Tumor Hospital
Triple Negative Breast Cancer (TNBC)
A Study of TQB2450 Injection and Anlotinib Hydrochloride Capsules to Treat Triple Negative Breast Cancer (TNBC)
The purpose of this study is to evaluate the efficacy and safety of PD-L1 inhibitorin in combination with Anlotinib treatment for patients with triple receptor negative breast cancer treated after failure of standard therapy…
- Trial name
- NCT03855358
- Testing
- TQB2450 Injection and Anlotinib Hydrochioride Capsules
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Evaluating the Efficacy of Trop-2 ADC Combination Therapy in Advanced Triple-Negative Breast Cancer
A Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast Cancer
Research purposes: the research design in the late more than 2 lines TNBC prospective, multicenter, cohort study, respectively to observe Trop2 - ADC joint PD - 1 single or combined anti-angiogenesis drugs (macromolecular single…
- Trial name
- NCT06878625
- Testing
- Sacituzumab Govitecan combined with Toripalimab, Sacituzumab govitecan combined with anti-angiogenesis
- Where
- China
- Volunteers
- 138 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Small Cell Lung Cancer (SCLC), SCLC, Extensive Stage
A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer
This is a phase II study evaluating a new combination therapy for untreated extensive-stage small cell lung cancer. The treatment involves an initial phase with the drug Bemotuzumab plus standard chemotherapy and anlotinib…
- Trial name
- NCT07358676
- Testing
- Bemotuzumab + Anlotinib + Chemotherapy + Radiotherapy
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Endometrial Cancer
Anti-PD-1 Antibody Combined With Anlotinib in the Treatment of Endometrial Cancer
The purpose of the study is to evaluate the Efficacy and safety of Anti-PD-1 antibody combined With anlotinib in the treatment of recurrent or advanced endometrial cancer.
- Trial name
- NCT04157491
- Testing
- anlotinib and anti PD-1 antibody
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Sun Yat-sen University
Clear Cell Sarcoma (CCS)
Vebreltinib for Advanced or Metastatic CCS
This is a prospective, cohort, multicenter study. Cohort 1 is treatment group. All eligible subjects will receive Vebreltinib (200 mg bid po) after signing the informed consent and meeting the inclusion/exclusion criteria, until…
- Trial name
- NCT07153887
- Testing
- Vebreltinib, Standard medical treatment
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Non-Small Cell Lung Cancer
Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC
This study is a single-center, prospective, single-arm exploratory clinical study of hypofractionated radiotherapy followed by tislelizumab and anlotinib neoadjuvant and adjuvant therapy.
- Trial name
- NCT06379087
- Testing
- Anlotinib Hydrochloride Capsule, Tislelizumab Injection, Hypofractionated Radiotherapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Ji Yongling
Non Small Cell Lung Cancer
Anlotinib Combined With Nivolumab for Non-Small Cell Lung Cancer
This study evaluates the safety and efficacy of anlotinib in combination with nivilumab as second-line treatment in advanced NSCLC patients.
- Trial name
- NCT04211896
- Testing
- Anlotinib, Nivolumab
- Volunteers
- 70 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Healthy Volunteer
Catequentinib Hydrochloride (AL3818) Drug-Drug Interaction Study in Healthy Volunteers
This is a non-randomized, open-label, fixed-sequence drug-drug interaction study to evaluate the effects of itraconazole and ticagrelor on the pharmacokinetics of catequentinib hydrochloride (AL3818) in healthy volunteers.
- Trial name
- NCT07438886
- Testing
- AL3818 Capsule, Itraconazole capsule, Ticagrelor Tablets
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Advenchen Laboratories Nanjing Ltd.
Locally Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer
mFOLFIRINOX Plus Anlotinib and Sintilimab for Advanced Pancreatic Cancer
This study is a prospective, single-arm, multicenter, phase Ib/II clinical trial that treats previously untreated patients with locally advanced or metastatic pancreatic cancer using mFOLFIRINOX in combination with anlotinib and…
- Trial name
- NCT06761027
- Testing
- Anlotinib combined with Sintilimab
- Where
- 4 sites in China
- Volunteers
- 29 people
- Sponsor
- Fujian Provincial Hospital
Breast Cancer
Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer
This study will evaluate the safety, tolerability and efficacy of anlotinib and trastuzumab deruxtecan in human epidermal growth factor receptor 2 (HER2)-low unresectable and/or metastatic breast cancer who had received ≤1 line…
- Trial name
- NCT06331169
- Testing
- Anlotinib, Trastuzumab deruxtecan
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Fudan University
Ovarian Carcinoma, Survival Outcomes
Niraparib Plus Anlotinib for Recurrent Ovarian Cancer
This is a phase II trial to explore efficacy and safety of niraparib in combination with anlotinib based on CA 125 level in newly diagnosed ovarian cancer.
- Conditions
- Ovarian Carcinoma, Survival Outcomes, Adverse Events, Niraparib
- Trial name
- NCT05311579
- Testing
- Niraparib plus anlotinib
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Lei Li
Glioblastoma
Pilot Study of Anlotinib With STUPP Regimen for Patients With Newly Diagnosed Glioblastoma
The purpose of this study is to test the the efficacy and safety of Anlotinib in combination with STUPP regimen for patients with newly diagnosed glioblastoma.
- Trial name
- NCT04119674
- Testing
- Drug is Anlotinib., Drug is Temozolomide Capsule., Radiotherapy was initiated 4 to 6 weeks postoperatively.
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Zhejiang Cancer Hospital
NSCLC
Toripalimab Combined With Anlotinib and SBRT in Patients With Untreated Brain Metastases of Driven Gene-negative NSCLC
The purpose of this study is to explore the efficacy and safety of toripalimab combined with anlotinib and SBRT for non-driver gene mutation untreated brain metastases non-small Cell Lung Cancer.
- Trial name
- NCT05021328
- Testing
- Toripalimab, Anlotinib, SBRT 7Gy✖️5 QD
- Where
- China
- Volunteers
- 13 people
- Sponsor
- Hubei Cancer Hospital
Limited Stage Small Cell Lung Cancer
This is a Two-cohort, Exploratory Clinical Study Assessing the Activity of Benmelstobart Combined With Chemotherapy With or Without Anlotinib in Resectable Limited-Stage Small Cell Lung Cancer
A total of 66 patients were enrolled in this exploratory study and randomly assigned to cohort 1 and cohort 2, with 33 patients in each group.
- Trial name
- NCT06978153
- Testing
- benmelstobart combined with chemotherapy and anlotinib, benmelstobart combined with chemotherapy
- Volunteers
- 66 people
- Sponsor
- Tang-Du Hospital
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
This is an single-arm, multicenter phase II study to evaluate the safety and efficacy of Sacituzumab Tirumotecan (sac-TMT) plus anlotinib in previously treated extensive-stage small cell lung cancer (ES-SCLC).
- Trial name
- STAR-01 (NCT07501169)
- Testing
- Sacituzumab Tirumotecan and Anlotinib
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Sichuan University